U.S. markets open in 5 hours 35 minutes
  • S&P Futures

    3,418.25
    -33.50 (-0.97%)
     
  • Dow Futures

    27,889.00
    -300.00 (-1.06%)
     
  • Nasdaq Futures

    11,571.25
    -92.25 (-0.79%)
     
  • Russell 2000 Futures

    1,613.90
    -21.70 (-1.33%)
     
  • Crude Oil

    38.68
    -1.17 (-2.94%)
     
  • Gold

    1,901.60
    -3.60 (-0.19%)
     
  • Silver

    24.33
    -0.35 (-1.42%)
     
  • EUR/USD

    1.1847
    -0.0021 (-0.18%)
     
  • 10-Yr Bond

    0.8410
    0.0000 (0.00%)
     
  • Vix

    29.91
    +1.80 (+6.40%)
     
  • GBP/USD

    1.3017
    -0.0021 (-0.16%)
     
  • USD/JPY

    104.8000
    +0.1100 (+0.11%)
     
  • BTC-USD

    13,061.19
    -15.83 (-0.12%)
     
  • CMC Crypto 200

    262.41
    +0.95 (+0.37%)
     
  • FTSE 100

    5,860.28
    +74.63 (+1.29%)
     
  • Nikkei 225

    23,494.34
    -22.25 (-0.09%)
     

Aptevo Therapeutics, Analyst Coverage, ADAPTIR Platform and Recent Drug Asset Sale

NEW YORK, NY / ACCESSWIRE / October 10, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Aptevo Therapeutics Inc. (APVO), a clinical-stage biotechnology company focused on novel oncology and hematology therapeutics.

On August 31st, Aptevo announced that it has agreed to sell its three marketed hyperimmune products to Saol Therapeutics. The three products that Saol will get are all coming from Aptevo's hyperimmune portfolio and are WinRho SDF for autoimmune platelet disorder and hemolytic disease of the newborn; HepaGam B for the prevention of Hepatitis B following liver transplantation and for treatment following hepatitis B exposure; and VARIZIG for treatment following exposure to varicella zoster virus for individuals with compromised immune systems.

Read the details of the asset sale and how the proceeds may impact the company READ MORE

Copy and paste to your browser may be required to view the report - http://tradersnewssource.com/aptevo-therapeutics/

ADAPTIR is a modular protein technology platform that can generate highly-differentiated, bispecific antibodies with unique mechanisms of action to treat cancer or various autoimmune diseases. Furthermore, it can do so relatively quickly and comparatively cheaply when looked at against the cost of developing a unique asset in this type of oncology indication.

On Oct. 2nd, 2017 the company announced new information on the Company's proprietary next-generation ADAPTIR™ protein therapeutic platform was presented at the 8th Annual World Bispecific Summit in Boston, MA, September 26-28, 2017.

Aptevo's next generation ADAPTIR platform, highlights improvements that have led to the development of new ADAPTIR candidates with increased stability, superior manufacturability, and antibody expression levels.

Investigate the ADAPTIR platform and the full APVO product pipeline here READ MORE

Copy and paste to your browser may be required to view the report - http://tradersnewssource.com/aptevo-therapeutics/

Disclosure

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Vikas Agrawal, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

SOURCE: Traders News Source